DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.

Author(s): Hadizadeh DR, Von Falkenhausen M, Kukuk GM, Schoneseiffen K, Gieseke J, Schild HH, Willinek WA

Affiliation(s): Department of Radiology, University of Bonn, Sigmund-Freud Strasse 25, 53127 Bonn, Germany. dr.hadizadeh@uni-bonn.de

Publication date & source: 2010-03, AJR Am J Roentgenol., 194(3):821-9.

Publication type: Comparative Study; Research Support, Non-U.S. Gov't

OBJECTIVE: The purpose of this study was to compare a macrocyclic 1.0 M contrast agent with a linear ionic 0.5 M contrast agent at equimolar dosage in regard to image quality and number of vessel segments visualized at abdominal dynamic contrast-enhanced 3D MR angiography. SUBJECTS AND METHODS: In an intraindividual comparative study, 15 patients (six women, nine men; mean age, 53 +/- 12.1 years; range, 25-72 years) underwent 32 1.5-T whole-body contrast-enhanced 3D MR angiographic examinations performed with parallel imaging technique. At random and in separate sessions, each patient was examined after IV injection of 0.1 mmol/kg body weight 1.0 M macrocyclic gadobutrol and 0.5 M linear ionic gadopentetate dimeglumine. Three-dimensional data sets were acquired in the arterial, portal venous, and venous phases with identical imaging protocols. Quantitative analysis included contrast measurements of vessels compared with adjacent background tissue (Student's t test). Qualitative analysis was performed independently by two radiologists with regard to visualization of arterial and venous vessel segments and overall image quality (Wilcoxon's test). RESULTS: Visualization of individual vessel segments was rated significantly better after administration of 1.0 M macrocyclic gadobutrol compared with 0.5 M linear ionic gadopentetate dimeglumine (p < 0.001). Overall image quality was superior with 1.0 M macrocyclic gadobutrol, but the difference was not significant. Vessel-to-background contrast after injection of 1.0 M macrocyclic gadobutrol was significantly higher (arterial phase, 0.90, p = 0.02; portal venous phase, 0.78, p = 0.0002; venous phase, 0.74, p = 0.0002) compared with 0.5 M linear ionic gadopentetate dimeglumine (arterial phase, 0.89; portal venous phase, 0.73; venous phase, 0.67). CONCLUSION: At abdominal contrast-enhanced 3D MR angiography, depiction of small abdominal vessels was significantly better and vessel-to-tissue contrast significantly higher with 1.0 M macrocyclic gadobutrol than with an equimolar dose of 0.5 M linear ionic gadopentetate dimeglumine.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017